Stay updated on Pembrolizumab+Cisplatin+IMRT in Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cisplatin+IMRT in Head & Neck Cancer Clinical Trial page.

Latest updates to the Pembrolizumab+Cisplatin+IMRT in Head & Neck Cancer Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new Revision: v3.3.3 entry appeared and the references to HHS Vulnerability Disclosure and Revision: v3.3.2 were removed from the page footer. These are minor maintenance updates that do not affect study details or user-facing content, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedThe history shows a new revision v3.3.2 and removal of v3.2.0, indicating administrative updates to the record rather than changes to trial data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedNotice about government funding and operating status was removed from the page. This does not affect the study data, versions, or the history records of the trial.SummaryDifference0.7%

- Check64 days agoChange DetectedThe Record History shows updates to Study Status and Quality Control Review across versions, including new QC return notes and related status changes.SummaryDifference0.1%

- Check93 days agoChange DetectedAdded a prominent operating-status notice and a v3.2.0 version tag, replacing the prior v3.1.0 revision.SummaryDifference12%

- Check100 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab+Cisplatin+IMRT in Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cisplatin+IMRT in Head & Neck Cancer Clinical Trial page.